What is the intrinsic value of Bmy?
As of 2025-06-07, the Intrinsic Value of Bristol-Myers Squibb Co (BMY) is
13.31 USD. This Bmy valuation is based on the model Peter Lynch Fair Value.
With the current market price of 48.41 USD, the upside of Bristol-Myers Squibb Co is
-72.50%.
Is Bmy undervalued or overvalued?
Based on its market price of 48.41 USD and our intrinsic valuation, Bristol-Myers Squibb Co (BMY) is overvalued by 72.50%.
13.31 USD
Intrinsic Value
Bmy Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(880.16) - (81.63) |
(131.99) |
-372.7% |
| DCF (Growth 10y) |
(78.95) - (764.74) |
(122.42) |
-352.9% |
| DCF (EBITDA 5y) |
(39.93) - (42.49) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(45.53) - (49.29) |
(1,234.50) |
-123450.0% |
| Fair Value |
13.31 - 13.31 |
13.31 |
-72.50% |
| P/E |
53.15 - 79.99 |
63.77 |
31.7% |
| EV/EBITDA |
51.64 - 161.52 |
88.28 |
82.4% |
| EPV |
163.53 - 223.24 |
193.38 |
299.5% |
| DDM - Stable |
37.34 - 239.50 |
138.42 |
185.9% |
| DDM - Multi |
(48.49) - (217.86) |
(76.84) |
-258.7% |
Bmy Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
98,518.23 |
| Beta |
0.14 |
| Outstanding shares (mil) |
2,035.08 |
| Enterprise Value (mil) |
137,354.22 |
| Market risk premium |
4.60% |
| Cost of Equity |
6.90% |
| Cost of Debt |
4.47% |
| WACC |
5.89% |